argenx (ARGX) Competitors

argenx (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.

Which has more volatility & risk, ARGX or BNTX?

argenx has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.

Do analysts recommend ARGX or BNTX?

argenx currently has a consensus price target of $530.74, suggesting a potential upside of 41.35%. BioNTech has a consensus price target of $120.40, suggesting a potential upside of 39.01%. Given argenx's stronger consensus rating and higher probable upside, research analysts plainly believe argenx is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	1 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.71
BioNTech	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Which has stronger valuation & earnings, ARGX or BNTX?

BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$1.27B	17.40	-$295.05M	-$5.14	-72.40
BioNTech	$4.13B	4.98	$1.01B	$4.12	21.02

Do institutionals and insiders hold more shares of ARGX or BNTX?

60.3% of argenx shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 2.4% of argenx shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in ARGX or BNTX?

argenx received 484 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.67% of users gave argenx an outperform vote while only 42.05% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
argenx	Outperform Votes 595 65.67%	Underperform Votes 311 34.33%
BioNTech	Outperform Votes 111 42.05%	Underperform Votes 153 57.95%

Does the media favor ARGX or BNTX?

In the previous week, argenx had 3 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for argenx and 4 mentions for BioNTech. argenx's average media sentiment score of 1.47 beat BioNTech's score of 1.21 indicating that argenx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenx	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ARGX or BNTX more profitable?

BioNTech has a net margin of 24.26% compared to argenx's net margin of -23.26%. BioNTech's return on equity of 4.60% beat argenx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenx	-23.26%	-16.97%	-15.26%
BioNTech	24.26%	4.60%	4.12%

Summary

argenx beats BioNTech on 11 of the 19 factors compared between the two stocks.